; Skip to content

Assessing a New Investigational Enzyme Replacement Therapy in CF Patients with EPI

Search Clinical Trials

Trial Objectives


Exocrine pancreatic insufficiency (EPI), a condition that leads to malnutrition and digestive symptoms, is common among people with cystic fibrosis (CF). Pancreatic enzyme replacement therapy (PERT) is a standard treatment for EPI, but current PERT therapies require taking large doses of medication and do not address all nutrient malabsorption in the digestive tract. Researchers want to know if an investigational oral treatment called ANG003 is safe and to evaluate its effects on nutrient absorption.

During study visits, participants will receive a physical exam and complete questionnaires about their bowel habits and digestion symptoms. On the second and fourth study visits, patients will be asked to eat prepared meals and complete a nutrient absorbance test and have multiple blood samples taken.

Who Can Participate


Adults aged 18 years and older with exocrine pancreatic insufficiency due to cystic fibrosis, who are also on a stable dose of pancreatic enzyme replacement therapy (PERT).

Age: 18+ Gender Any

Estimated Time Commitment


Six in-person visits and two phone calls, occurring within 23-26 days, two in-person visits will require being in the clinic for up to 12 hours

Payment & Reimbursement


Payment Provided

Travel Reimbursement Available

Trial Contact


For more information, contact:

Salma Moreno
303.270.2861

Request More Information

Trial Location


National Jewish Main Campus, Denver, CO

Trial Sponsors


Anagram Therapeutics

Principal Investigators

Jeffrey B. King

Jeffrey B. King, MD

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required